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Abstract
We aimed to investigate whether combination of vitamin D and iron supplementation, comparing vitamin D alone, could modify
bone turnover, inflammatory, oxidative stress, and metabolic markers. Eighty-seven women with hemoglobin (Hb) ≤ 12.7 g/dL and
25OHD ≤ 29 ng/mL vitamin D deficiency/insufficiency aged 18–45 years were randomly assigned into two groups: (1) receiving
either 1000 IU/day vitamin D3 plus 27 mg/day iron (D-Fe); (2) vitamin D3 plus placebo supplements (D-P), for 12 weeks. In D-Fe
group, significant decrease in red blood cells (RBC) (P = 0.001) and hematocrit (Hct) (P = 0.004) and increases in mean corpuscular
hemoglobin concentration (MCHC) (P = 0.001), 25OHD (P < 0.001), osteocalcin (P < 0.001), high-density cholesterol (HDL) (P =
0.041), and fasting blood sugar (FBS) (P < 0.001) were observed. D-P group showed significant decrease in RBC (P < 0.001), Hb
(P < 0.001), Hct (P < 0.001), mean corpuscular volume (MCV) (P = 0.004), mean corpuscular hemoglobin (MCH) (P < 0.001),
MCHC (P = 0.005), serum ferritin (P < 0.001), and low-density cholesterol (LDL) (P = 0.016) and increases of 25OHD (P < 0.001),
osteocalcin (P < 0.001), C-terminal telopeptide (CTX) (P = 0.025), triglyceride (TG) (P = 0.004), FBS (P < 0.001), and interleukin-6
(IL-6) (P = 0.001) at week 12. After the intervention, the D-P group had between-group increases in mean change in the osteocalcin
(P = 0.007) and IL-6 (P = 0.033), and decreases in the RBC (P < 0.001), Hb (P < 0.001), Hct (P < 0.001), and MCV (P = 0.001),
compared with the D-Fe group. There were significant between-group changes inMCH (P < 0.001), MCHC (P < 0.001), ferritin (P
< 0.001), and serum iron (P = 0.018). Iron–vitamin D co-supplementation does not yield added benefits for improvement of bone
turnover, inflammatory, oxidative stress, and metabolic markers, whereas, vitamin D alone may have some detrimental effects on
inflammatory and metabolic markers. IRCT registration number: IRCT201409082365N9
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Introduction
Vitamin D deficiency and anemia are problems that are still
common in the world. It has been estimated that more than a
billion people around the world suffer from hypovitaminosis
D (25OHD ≤ 75 nmol/L (< 30 of ng/mL))[1].Furthermore, the
global prevalence of anemia was estimated at 1.62 billion
people between1993 and 2005, mostly caused by iron defi-
ciency [2].
Vitamin D has several valuable functions. Severe vitamin
D deficiency (25OHD ≤ 15 nmol/mL) causes rickets in chil-
dren and osteomalacia in adults, and eventually bone fractures
[3]. The reason is attributed to secondary hyperparathyroidism
and a consequent increase in bone turnover. Vitamin D sup-
plementation may improve bone mass density and reduce
bone turnover and risk of fracture [4]. Additionally, the pro-
duction of inflammatory cytokines, such as tumor necrosis
factor-α (TNF-α), interferon-γ, interleukin-2, interleukin-9,
and interleukin-22, is inhibited by vitamin D, whereas the
production of anti-inflammatory cytokines such as interleu-
kin-3, interleukin-4, interleukin-5, and interleukin-10 is initi-
ated by vitamin D [5]. It has also been demonstrated that risk
of diseases associated with increased DNA damage, caused by
oxidative stress, is more in patients with vitamin D deficiency
or insufficiency [6]. Researchers suggested that vitamin D
may improve some of cardiovascular disease risk factors such
as serum lipids, fasting plasma glucose, and oxidative stress
[7, 8].
Recent years, the relationship between anemia and vitamin
D deficiency has attracted a great deal of attention from re-
searchers. A low level of vitamin D in Asian children with
IDA has been reported [9, 10]. A recent systematic review
showed a positive relationship between iron status and vita-
min D [11]. One of the possible explanations that has been
discussed in the literature is the role of iron in the hydroxyl-
ation of vitamin D by cytochrome P450 isoforms [12]. These
enzymes are dependent on electron donors including ferredox-
in and ferredoxin reductase which contain heme group. The
effect of iron on vitamin D activation is controversial; intra-
muscular injection of iron in iron-deficient infants increased
vitamin D levels after 2 months[13], while treatment of iron
deficiency in adult women had no effect on 25(OH)-D con-
centrations [14]. Additionally, iron as a cofactor for lysyl
prolyl hydroxylase enhances bone strength [15] and its chron-
ic deficiency may lead to osteoporosis in later life. A positive
relationship between bone mass density at the proximal radius
and serum ferritin levels has been reported in adolescent girls
[16].
To the best of our knowledge, few interventional studies
have investigated the effects of iron supplementation on vita-
min D concentration, bone turnover, metabolic, inflammatory,
and oxidative stress biomarkers. The present study aimed to
investigate whether combination of vitamin D and iron
supplementation, comparing vitamin D and placebo, could
modify vitamin D status, some bone turnover markers, select-
ed markers of inflammation and oxidative stress, lipid pro-
files, and glucose level in child-bearing age women with low
levels of hemoglobin (Hb) and vitamin D.
Materials and Methods
This study was a triple-blind, randomized, clinical trial con-
ducted in Kermanshah, Iran, duringMay–August 2015. Seven
hundred women aged 18–45were recruited at health care cen-
ters and screened for vitamin D deficiency and anemia.
Inclusion criteria were as follows: healthy women, non-smok-
er, non-pregnant, non-lactating, have a body mass index
(BMI) between 18.5 and 29.9 kg/m2, with Hb ≤ 12.7 g/dL
and 25(OH)-D < 30 ng/mL. Iron deficiency anemia is diag-
nosed with hemoglobin levels less than 12 g/dL. However,
Beutler and Waalen have suggested considering the altitude
of the residence site of people for the screening of anemia
[17]; as this cut-off could be increased to 4% per 1000 meters
above sea level [18], Hb ≤ 12.7 g/dL was used for anemia
screening. Vitamin D deficiency was defined as 25OHD <
20 ng/mL and vitamin D insufficiency as a level of 20–29
ng/mL [19].
Females were excluded if they had amenorrhea, meno-
pause, thalassemia, hemochromatosis, inflammatory bowel
diseases, Crohn’s disease, gastric ulcers, celiac disease, gas-
trointestinal bleeding disorders, kidney diseases, blood dona-
tion, or taking any kind of the medications with an impact on
hematologic and biochemical markers during the 4 past
months (i.e., dietary supplements and drugs like nonsteroidal
anti-inflammatory, anti-diabetic, or lipid-lowering agents).
The sample size was calculated for detecting a 21.1 ng/mL
increase [20] in the concentrations of vitamin D in Fe-D group
as compared with P-D group, according to the dose of vitamin
D used in the present study, at a significance level of 0.05 and
90% power. A study size of 76 females was obtained.
Assuming a 25% drop-out rate, a total of 100 women partic-
ipated in the intervention. As most of screened women had
normal hemoglobin levels (≥ 12.7 g/dL), totally, 100 women
were recruited onto the trial. Baseline characteristics of partic-
ipants are shown in Table 1.
This study was in agreement with the Declaration of
Helsinki and was approved by the Ethics Committee of the
Isfahan University of Medical Sciences (IR.mui.rec.1394.3/
291) and the Iran University of Medical Sciences
(IR.IUMS.REC.1394.25971). Written informed consent was
obtained from all participants after explaining the purpose and
process of the study, and the intervention was registered at
www.irct.ir, IRCT201409082365N9. This study followed
the CONSORT guidelines and the details of trial are
presented in Fig. 1.
Changes in Bone Turnover, Inflammatory, Oxidative Stress, and Metabolic Markers in Women Consuming Iron... 2591
An independent researcher used a random allocation se-
quence to randomly allocate females in a 1:1 ratio to receive
1000 IU cholecalciferol and 27 mg ferrous sulfate or 1000 IU
cholecalciferol and matched placebo in terms of shape, color,
and taste for 12 weeks. Vitamin D, iron, and placebo tablets
were manufactured by Jalinous (Jalinous pharmaceutical
Company, Tehran, Iran), Maad (Maad Pharmacy, Tehran,
Iran), and Tehran University of Medical Sciences (Roshd
Pharmaceutical Incubation Center, Tehran, Iran), respectively.
The independent researcher packaged iron and placebo tablets
in boxes and consecutively numbered according to a
computer-generated randomization list. Using opaque enve-
lopes, the boxes were delivered to the study supervisor for
random allocation. An order number was assigned to each
female and the supplements were given in the corresponding
pre-packed box every 4 weeks. The allocation was masked
from the participants, study supervisor, staff involved in out-
come assessment, and statistician until drafting results.
Assessed for eligibility (n=700)
Excluded (n=600)
Not meeting inclusion criteria (n=500)
Declined to participate (n=90)
Other reasons (n=10)
Analysed (n=39)
Discontinued intervention (9 of them refused further 
participation in the study because of personal reasons 
and 2 of them withdrew due to getting pregnant) (n=11)
Allocated to Vitamin D-Placebo intervention 
(n=50)
Discontinued intervention (gastrointestinal 
complaints) (n=2)








Fig. 1 Flowchart of participants
Table 1 Characteristics of the
participants at baseline according
to randomly assigned group
All (n = 87) D-Fe (n = 48) D-P (n = 39) P value
Age, year 34. 6 ± 7.4 34.1 ± 7.6 35.2 ± 6.7 0.094*
Married, n (%) 62 (62.0) 30 (62.0) 32 (64.0) 0.267*
Body weight, kg 70.2 ± 14.5 70.7 ± 14.9 69.7 ± 14.1 0.714*
BMI, kg/m2 27.2 ± 1.2 26.6 ± 1.2 27.8 ± 1.2 0.304*
Physical activity level, MET/h 1459.1 ± 2946.6 1430.7 ± 2062.2 1484.9 ± 3591.0 0.892*
Data are expressed as mean ± SD except for marriage status
BMI body mass index, MET metabolic equivalent
*Obtained from independent samples T test
Abiri et al.2592
Women were instructed to take both tablets daily and not
change their habitual dietary intake and physical activity.
Compliance with the intervention was assessed using the
levels of 25OHD, serum iron, and number of remaining pills.
Additionally, all participants were contacted monthly during
the study period.
Primary Outcome
The concentration of 25OHDwasmeasured at baseline and 12
weeks. Blood samples were collected at the time of screening
and at the end of the intervention after a 12-h fasting period.
Whole blood (3 cc) was used to assess complete cell blood
count. Serum was obtained from remaining blood after centri-
fugation at 1000g for 15 min, stored at – 80 °C, and analyzed
after the study was completed. Serum vitamin D was mea-
sured by an ELISA kit, with intra- and inter-assay coefficients
of variation of 5.6 and 6.4%, respectively (25-hydroxyvitamin
D EIA, Immunodiagnostic Systems, IDS, UK).
Secondary Outcome
Secondary outcomes included hematologic indices (complete
cell blood count, ferritin, serum iron, transferrin saturation,
and total iron binding capacity (TIBC)); bone turnover
markers (osteocalcin, C-terminal telopeptide (CTX), parathy-
roid hormone (PTH), alkaline phosphatase (ALP) enzyme ac-
tivity and enzyme mass); inflammatory markers (interleukin-
6, TNF-α, high-sensitivity C-reactive protein (hsCRP)); oxi-
dative stress markers (total antioxidant capacity (TAC) and
malondialdehyde, fasting blood sugar (FBS)); and lipid profile
(total cholesterol (TC), low-density cholesterol (LDL), low-
density cholesterol (HDL), and triglyceride (TG)).
Measurement of ferritin was done by an ELISA kit.
Sensitivity and intra-assay coefficient of variation for ferritin
were 0.5 ng/mL and 8.7%, respectively. Serum iron was mea-
sured using enzymatic photometry. Transferrin was defined
by the immunotorbidimetric method.
The bone formationmarker, serum osteocalcin, wasmeasured
by an ELISA commercial kit with 0.25 ng/mL sensitivity and
intra-assay coefficient of variation of 5.7% (ZellBioGmbH,Ulm,
Germany). The bone resorption marker, serum CTX, was deter-
mined by an ELISA commercial kit with 10 pg/mL sensitivity
and intra-assay coefficient of variation of 6.1% (ZellBio GmbH,
Ulm, Germany). PTH was measured with the use of an ELISA
kit (ZellBio GmbH, Ulm, Germany, sensitivity: 0.8 pg/mL and
intra-assay coefficient of variation: 5.4%). ALPmasswas defined
using an ELISA commercial kit (ZellBioGmbH,Ulm,Germany,
sensitivity: 0.1 ng/mL and intra-assay coefficient of variation:
5.8%), and ALP activity was measured by colorimetry.
hsCRP was measured with the use of an ELISA kit
(Diagnostics BiochemCanada Inc., Ontario, Canada, sensitiv-
ity: 10 ng/mL and intra-assay coefficient of variation: 6.2%).
Serum interleukin-6 was determined by an ELISA commer-
cial kit with 2 pg/mL sensitivity (Diaclone, Besancon,
France). Serum TNF-α was measured by an ELISA commer-
cial kit with 8.5 pg/mL sensitivity and intra-assay coefficient
of variation of 6.6% (Diaclone, Besancon, France). TAC was
defined as using an ELISA commercial kit (ZellBio GmbH,
Ulm, Germany, sensitivity: 0.1 mM and intra-assay coeffi-
cient of variation: 5.1%), and malondialdehyde was measured
by an ELISA commercial kit (ZellBio GmbH, Ulm, Germany,
sensitivity: 0.1 mM and intra-assay coefficient of variation:
4.8%). FBS and lipid profiles were measured by enzymatic
colorimetric methods.
Height was measured to the nearest 0.1 cm using a
stadiometer. Body weight was measured to the nearest 100 g
on a scale. BMI was calculated as weight (kg)/height (m)2.
The body fat mass was determined with the same scale used
for measuring weight. At the beginning and at the end of the
intervention, dietary intakes were assessed with a 24-h food
recall for 3 days (2 weekdays and 1 weekend day) and energy,
macronutrients, and micronutrient intakes were estimated by
nutritionist 4 software. Physical activity level was assessed
using International Physical Activity Questionnaire, short for-
mat [21], at baseline and the end of the study. Sun exposure
was defined by a validated questionnaire [22].
Statistical Analysis
Statistical analyses were performed using SPSS software (IBM
Corp. Released 2013. IBM SPSS Statistics for Windows,
Version 22.0. Armonk, NY: IBM Cor), and P value < 0.05
was considered statistically significant. Normal distribution of
the outcome variables was defined using the Shapiro–Wilk test.
Changes within the groups from baseline to week 12 were
analyzed using paired samples T tests or Wilcoxon signed rank
test whenever the distributions of the variables were not normal.
Change on each variable was calculated as pre-intervention
minus post-intervention values for each subject, and then mean
value for the change for each groupwas calculated. To compare
mean changes in variables between groups, theMann–Whitney
or independent samples T test was used. One-way analysis of
covariance (ANCOVA) was also conducted to adjust the effect
of baseline differences on the intervention results, whenever
there were significant differences in baseline values between
groups. Continuous variables are presented as mean and stan-
dard deviations (mean ± SD). Categorical variables are demon-
strated as frequencies and percentages. Chi-square test was used
to assess the differences between categorical variable.
Results
Ages of the volunteers were 35.18 ± 6.74 and 34.08 ± 7.64
years for the D-P and D-Fe groups, respectively, without
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significant differences between the groups (Table 1). No sig-
nificant differences between groups were found in body
weight, BMI, and physical activity level at baseline.
A total of 87 women completed the study. Eleven women
dropped out in the D-P group; nine of them refused further
participation in the study because of personal reasons and two
of them withdrew due to getting pregnant. Two females in the
D-Fe group were excluded due to gastrointestinal complaints.
Table 2 shows the intervention results. There were signif-
icant differences in baseline values of red blood cells (P =
0.013), MCV (P = 0.006), MCH (P = 0.006), ferritin
(0.041), alkaline phosphatase enzyme mass (P = 0.034), alka-
line phosphatase enzyme activity (P = 0.033), CTX (P =
0.032), parathyroid hormone (P = 0.045), hsCRP (0.007),
total antioxidant capacity (P = 0.005), total cholesterol (P =
0.008), triglyceride (P = 0.011), LDL (P = 0.006), and HDL
(P = 0.008) between D-Fe and D-P groups.
In the D-Fe group, significant decreases in red blood cells (P
= 0.001), hematocrit (P = 0.004), and weight (P = 0.012) and
increases in 25OHD (P < 0.001), MCHC (P = 0.001),
osteocalcin (P < 0.001), fasting blood sugar (P < 0.001), and
HDL (P = 0.041) were observed. The D-P group showed signif-
icant decrease of RBC (P < 0.001), Hb (P < 0.001), hematocrit
(P < 0.001), MCV (P = 0.004), MCH (P < 0.001), MCHC (P =
0.005), serum ferritin (P < 0.001), and LDL (P = 0.016) and
increases of 25OHD (P < 0.001), osteocalcin (P < 0.001), CTX
(P = 0.025), fasting blood sugar (P < 0.001), interleukin-6 (P =
0.001), and triglyceride (P = 0.004) at week 12.
After the intervention, the D-P group had between-group
decreases in mean change in the red blood cells (P < 0.001),
hemoglobin (P < 0.001), hematocrit (P < 0.001), andMCV (P
= 0.001), and increases in the osteocalcin (P = 0.007) and
interleukin-6 (P = 0.033), compared with the D-Fe group.
There were significant between-group changes in MCH (P <
0.001), MCHC (P < 0.001), ferritin (P < 0.001), and serum
iron (P = 0.018). Though MCH, MCHC, and serum iron in-
creased in the D-Fe group, these variables decreased in the D-
P group. Controlling for pre-intervention variance by
ANCOVA did not change the results for indices that had dif-
ferent initial values, except for triglyceride. The increase in
triglyceride concentration was higher in the D-P group after
adjusting for baseline values (P = 0.016).
Dietary characteristics of the females at baseline and week
12 are presented in Table 2. There were no changes in the intake
of macro- and micronutrients at week 12 compared with base-
line (Table 3). Sun exposure was similar in all volunteers at
baseline and after 12 weeks of intervention (Table 4).
Discussion
This study examined the advantages of adding iron to vitamin
D vs. vitamin D alone on bone turnover, inflammatory,
oxidative stress, and metabolic markers. The intervention
was performed in women with low levels of hemoglobin
and 25(OH)-D. However, iron plus vitamin D was not supe-
rior to vitamin D alone.
The usefulness of iron therapy in the treatment of anemia
has been proven, especially in those with deteriorated hema-
tologic condition [23]. However, supplementation with high
dose of ferrous sulfate in female athletes for 11 weeks did not
result in an improvement in hematologic parameters and had
only a preventive effect on reducing body iron which is in line
with the present study [24]. In our study, minor decreases in
hematologic indices were observed in the D-Fe group that is
physiologically implausible. It has also shown that serum
levels of transferrin saturation, ferritin, and hemoglobin di-
minished by using a fortified food product containing calcium
and vitamin D during 9 weeks [25]. Failure to see an increase
in these variables in the present study could be related to
menstruation [26] and insufficient iron dose used [27].
Further studies with different groups and interventions are
required.
The salutary effect of vitamin D on bone health is well
known. Vitamin D controls bone remodeling through induc-
ing ligand receptor activator of NF-kB, regulation of phos-
phate homeostasis by increasing fibroblast growth factor 23,
and increases bone response to mechanical stimulation via
mitogen-activated protein kinase signaling pathway [28]. It
has shown that consumption of 7000 IU/day cholecalciferol
for 26 weeks in vitamin D–deficient women can reduce PTH
and CTX and increase arm bone mass density [29]. A recent
study indicated that 1000 IU/day vitamin D supplementation
for 9 months decreased bone turnover markers [30].
Lerchbaum et al. evaluated the effects of 20,000 IU/week
vitamin D on bone turnover markers in 200 healthy men with
25OHD < 75 nmol/L in comparison to placebo. However,
after 12 weeks of supplementation, there was no significant
effect on bone metabolism or density [31]. In our study, it was
assumed that vitamin D plus iron supplementation versus vi-
tamin D alone would further increase 25OHD concentration,
further improve bone formation, and further reduce bone re-
sorption. We observed that both groups experienced approx-
imately the same increase of 25OHD, bone turnover markers
rose in both groups, and surprisingly, the bone formation
marker, osteocalcin, was significantly higher in the D-P
group. There are limited studies evaluating the effects of iron
on 25OHD and bone turnover markers. Published results of
the Safe-D study indicated that factors like age, body compo-
sition, and iron status have impact on bone turnover markers
[32]. Blanco-Rojo et al. reported no effects of iron-fortified
juice consumption on bone turnover markers in women with
ferritin < 40 ng/mL [33]. The 25OHD levels reduced com-
pared with baseline in both groups, with no difference be-
tween groups. In rats fed a diet low in iron, a sharp reduction
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propeptide (bone formation marker) and an increase in PTH
and tartrate-resistant acid phosphatase 5b (bone resorption
markers) have been observed [34]. However, the level of
25OHD in this study did not change. Toxqui et al. observed
a decrease in bone turnover markers and an increase in
25OHD when a group of women with iron deficiency anemia
received an iron and vitamin D–fortified skimmed milk for 16
weeks [35]. A recent study demonstrated no change in serum
levels of PTH and vitamin D binding protein after simulta-
neous supplementation of vitamin D and iron [36]. Recovery
from iron deficiency anemia has been associated with lower
bone remodeling without significant change in 25OHD level
[14]. There are several differences between our study and
similar trials that may justify our findings. These differences
include the presence of iron deficiency in all participants and
longer study duration. Additionally, in all of these studies,
procollagen type I N-terminal propeptide was measured that
is the most accurate marker of the bone formation [28].
However, 1,25(OH)2 D3 induces mRNA, synthesis, and se-
cretion of osteocalcin by human and rat bone cells in vitro
which is sensitive and specific for the evaluation of formation
in adults [37]. Unfortunately, none of these studies evaluated
the effect of iron and vitamin D compared with vitamin D
alone. Furthermore, we did not include a third group of iron-
placebo in our trial. The increased bone turnover can be at-
tributed to the coupling of formation and resorption. It has
reported that serum osteocalcin is increased in patients with
untreated osteomalacia [38]. So, it can be concluded that both
groups experienced enhanced formation coupled with resorp-
tion. Additionally, calcium intake was less than recommended
dietary intake in both groups. Low levels of calcium and phos-
phorus stimulate PTH secretion and consequent increased
1,25(OH)2 D3 concentration [39]. Both hormones increase
bone resorption to provide calcium and phosphorus required
for calcification, and this could be another reason for the lack
of decreased bone turnover in this trial. Four months supple-
mentation with 20,000 IU/week vitamin D in 399 subjects
with mean baseline 25OHD 34.0 nmol/L resulted in small
but significant reduction of procollagen of type 1 amino-
terminal propeptide (P1NP), without any effect on CTX,
Dickkopf-1, sclerostin, TNF-α, osteoprotegerin, and receptor
activator of nuclear factor ĸB ligand [40]. Those with high
baseline PTH who had a decrease in PTH after the interven-
tion, experienced higher decrease of P1NP and also significant
reduction of serum CTX and increased sclerostin. Authors
concluded that vitamin D supplementation is not effective or
may even exaggerate bone loss if not combined with sufficient
calcium intake. It is also seen that the response of bone turn-
over markers is different to osteoporosis treatments [41]; anti-
resorptive treatments, like bisphosphonates, cause an early
bone resorption and a delayed bone formation decrease, while
anabolic treatments such as teriparatide result in an initial
increase of bone formation markers and subsequent increase
Table 3 Habitual dietary intake of participants at baseline and after 12
weeks
Variables Groups
D-Fe (mean ± SD) D-P (mean ± SD)
Energy, kcal/day Before 1786.3 ± 544.9 1837.2 ± 498.4
After 1741.6 ± 382.6 1743.7 ± 566.9
P value* 0.955 0.706
Carbohydrate, g/day Before 234.7 ± 61.6 236.3 ± 52.1
After 234.1 ± 58.3 226.7 ± 61.3
P value* 0.759 0.500
Protein, g/day Before 58.7 ± 20.8 57.9 ± 18.2
After 57.1 ± 12.6 58.5 ± 14.1
P value* 0.860 0.695
Fat, g/day Before 75.8 ± 37.8 78.7 ± 34.7
After 65.7 ± 30.7 74.2 ± 39.3
P value* 0.283 0.413
Cholesterol, mg/day Before 142.6 ± 1.9 172.7 ± 2.2
After 138.8 ± 2.0 141.3 ± 2.2
P value* 0.837 0.273
Dietary fiber, g/day Before 10.8 ± 1.8 9.7 ± 1.6
After 15.1 ± 1.4 11.6 ± 1.5
P value* 0.087 0.094
Magnesium, mg/day Before 206.9 ± 97.0 205.4 ± 99.6
After 195.7 ± 73.7 192.2 ± 77.4
P value* 0.834 0.850
Phosphorous, mg/day Before 840.4 ± 363.1 810.3 ± 340.5
After 848.6 ± 310.4 845.8 ± 291.5
P value* 0.706 0.557
Iron, mg/day Before 12.7 ± 4.3 14.1 ± 5.3
After 12.0 ± 3.9 11.68 ± 4.7
P value* 0.706 0.184
Calcium, mg/day Before 538.7 ± 319.2 595.7 ± 272.5
After 584.6 ± 217.3 613.4 ± 282.5
P value* 0.209 0.902
Selenium, mg/day Before 0.10 ± 0.06 0.10 ± 0.05
After 0.13 ± 0.10 0.13 ± 0.03
P value* 0.325 0.629
Vitamin K, μg/day Before 102.8 ± 122.2 103.8 ± 156.8
After 112.7 ± 133.7 97.5 ± 100.9
P value* 0.727 0.482
Vitamin D, μg/day Before 0.9 ± 1.1 1.2 ± 1.6
After 0.9 ± 1.3 1.0 ± 1.4
P value* 0.28 0.91
Vitamin E, mg/day Before 4.0 ± 2.9 6.4 ± 4.5
After 3.6 ± 3.3 8.5 ± 5.9
P value* 0.082 0.112
Vitamin C, mg/day Before 44.2 ± 2.9 47.2 ± 2.4
After 62.3 ± 2.1 61.8 ± 2.2
P value* 0.085 0.161
*Obtained from paired samples T test & Wilcoxon Signed Ranks Test
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of bone resorption. It seems that the action of vitamin D in our
study was like an anabolic treatment.
Our study showed a significant increase of interleukin-6 in
D-P group without any effect on in none of groups. Previous
studies with vitamin D supplementation have shown conflict-
ing results. A decline in CRP has been reported among patients
in the intensive care unit after vitamin D supplementation [42],
while supplementation with 100,000 IU/day vitamin D2 or D3
had no clinically meaningful effect on hsCRP level [43].
Monthly intake of 1.25 mg vitamin D for 2 years could not
change inflammatory indexes like hsCRP, IL-6, IL-8, and IL-
10 in 200 patients with osteoarthritis and vitamin D deficiency
[44]. A meta-analysis on diabetic patients showed that vitamin
D supplementation could reduce hsCRP but not TNF-α and IL-
6 [45]. The difference in the results of studies could be due to
supplementation dosage, treatment period, and the population
studied. Higher serum concentration of hsCRP at baseline is
effective on the results of vitamin D interventions [46].
Furthermore, supplemental vitamin D has increased
interferon-γ and interleukin-10 in subjects that were vitamin
D insufficient compared with sufficient healthy adults [47].
Perhaps lack of reduction of inflammatorymarkers in this study
and similar studies is attributed to lower duration of interven-
tion and recruiting healthy subjects, because most studies with
positive results have been conducted in patients with inflam-
mation [48]. Besides, observed increased interleukin-6 in the
D-P group may be related to the lack of regulatory effect of
vitamin D on some inflammatory markers, low concentrations
of inflammatory markers at baseline, low dose of vitamin D,
and a higher percentage of patients with vitamin D deficiency.
Antioxidant effects of vitamin D were first established by
Wiseman in 1993 by the concept that vitamin D3 and the
active form 1,25(OH)2 D3 halted iron-dependent peroxidation
of liposomal lipid [49]. Vitamin D3 mega dose of (200,000
IU) increased total antioxidant capacity in vitamin D–
sufficient elderly women, and did not affect malondialdehyde
[50]. After 12 weeks of consumption of vitamin D3–fortified
doogh compared with plain doogh, significant decrease of
malondialdehyde and enhancement of glutathione and TAC
were revealed [51]. Failing to show positive results in the
present study may be related to differences in patients’ geno-
type for vitamin D receptor, low-dose supplements required
for reduction of lipid peroxidation, and insufficient time to
impact on oxidative stress markers.
Table 4 Sun exposure of
participants at baseline and after
12 weeks
Variables Groups P value
D-Fe (n (%)) D-P (n (%))
Sun exposure duration < 1 h/day Before* 35 (85.3) 32 (84.2) 0.526
After** 37 (90.2) 30 (78.9)
> 1 h/day Before* 6 (14.7) 6 (15.8)
After** 4 (9.8) 8 (21.1)
Time of sun exposure 10 am–3 pm Before* 28 (68.2) 23 (60.5) 0.099
After** 26 (63.4) 22 (57.8)
Other times Before* 13 (31.8) 15 (39.5)
After** 15 (36.6) 16 (42.2)
Sun exposure area Face Before* 14 (34.2) 15 (39.4) 0.264
After** 16 (39.0) 17 (44.7)
Hands Before* 5 (12.2) 1 (2.6)
After** 4 (9.7) 1 (2.6)
Face and hands Before* 17 (41.5) 18 (47.5)
After** 15 (36.6) 16 (42.2)
Other areas Before* 5 (12.1) 4 (10.5)
After** 6 (14.7) 4 (10.5)
Sun screen use Sometimes Before* 34 (82.9) 31 (81.6) 0.670
After** 35 (85.3) 31 (81.6)
Always Before* 7 (17.1) 7 (18.4)
After** 6 (14.7) 7 (18.4)
SPF of sunscreen < 50 Before* 34 (82.9) 35 (92.1) 0.322
After** 35 (85.3) 36 (94.7)
≥ 50 Before* 7 (17.1) 3 (7.9)
After** 6 (14.7) 2 (5.3)
SPF sun protection factor
*Obtained from chi-squared test
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According to some observational studies on type 2 diabetes
patients, vitamin D may have positive effects on glucose ho-
meostasis [52, 53]. However, a systematic review found a
weak correlation between vitamin D supplementation and de-
scending fasting blood glucose and addressing insulin resis-
tance challenge in patients with type 2 diabetes or impaired
glucose tolerance, while no effect was seen in subjects with
normal glucose tolerance [54]. In a recent systematic review
and meta-analysis on 20 randomized clinical trials including
1464 patients with diabetic nephropathy, vitamin D supple-
mentation had no impact on glycemic control indexes [55].
There are also some unpredictable findings. Supplementation
with 50,000 IU/week vitamin D for 8 weeks in healthy adults
> 65 years resulted in an increase in the number of people with
insulin resistance from 13.2% to 36.8% [56]. The mean ho-
meostatic model assessment of insulin resistance also in-
creased from 1.39 ± 1.34 to 5.27 ± 3.72. Also, in Cox propor-
tional hazard regression model, in contrast to multivariable
binary logistic regression model, in order to predict the asso-
ciation between serum 25OHD level and the incidence of type
2 diabetes, a positive relationship was observed at the highest
vitamin D quartile [57]. Here, an increase in FBSwas revealed
in our healthy young women that is inexplicable and should be
evaluated in future studies. Short duration of the study and
limited number of participants could confound our results.
After the intervention, a significant increase in TG and
decrease in LDL were observed in the D-P group, while
HDL increased significantly in the D-Fe group. In a meta-
analysis (including 4 clinical trials, three of them with poor
quality and high heterogeneity) to evaluate the effect of vita-
min D supplementation on cardiometabolic risk factors in
healthy adults, no significant effect was observed [58]. Some
studies have reported a positive relationship between 25OHD
and serum lipids [59, 60]. Ponda et al. observed that correcting
vitamin D deficiency by administering 50,000 IU of vitamin D
weekly during 8 weeks significantly increased LDL-
cholesterol in vitamin D–deficient high cardiovascular-risk
adults [61]. This controversy in results may be due to differ-
ences in study design, dose of vitamin, and participant’s con-
ditions. Furthermore, sufficient 25OHD has been attributed to
better physical health and healthy lifestyle [62]. Our partici-
pants’ vitamin D insufficiency may be related to non-specific
chronic diseases. Supplementation with 50 mg iron with
500 mg docosahexaenoic acid or placebo in 76 women suf-
fering from iron deficiency anemia caused significant de-
crease of apoAI in the group receiving iron and placebo
[63]. Because of no significant between-group differences
and small number of studies evaluating iron effects on cardio-
vascular health, it seems too early for conclusion.
The lack of effect of iron on vitamin D activation can be
related to one or more of the following reasons: (a) the length
of follow-up in studies evaluating bone markers is usually
longer than the duration of the present study; (b) the dose of
iron was not sufficient for iron status improvement; and (c) as
previously mentioned, cytochrome P450 contains iron; how-
ever, in an animal study conducted by Dhur et al., in 1989 to
assess the effects of different degrees of iron deficiency on
cytochrome P450 enzymes, it was suggested that modification
of iron-dependent enzymes may only happen after the third
stage of iron deficiency [64]. A recent study in rats demon-
strated negative effects of iron deficiency on renal 1α-
hydroxylase activity and bone formation [65]. However, the
authors concluded that the severity of iron deficiency anemia
in their animal model is rare in human subjects. To the best of
our knowledge, this is the first randomized, triple masked,
clinical trial to assess the effect of vitamin D–iron co-supple-
mentation, compared with vitamin D–placebo supplementa-
tion on bone health among healthy females. Strengths of the
current study included the study methodology and adjustment
of some confounding factors like physical activity level, sun
exposure, age, and body composition. Unwanted significant
increases of some metabolic and inflammatory biomarkers
show a special need for conducting further studies regarding
the effects of iron and vitamin D in individuals with concur-
rent vitamin d deficiency and iron deficiency anemia. Hence,
further studies should be performed to explore in depth the
effects of iron on vitamin D function and bone health.
This has some limitations which have to be pointed out.
Firstly, all women were healthy and all parameters were with-
in normal limits. It was assumed that most of participants with
low hemoglobin levels are iron deficient; however, ferritin
measurement did not prove our assumption and other reasons
that can cause anemia may also affect the results of the present
study. This study should have been performed in those with
ferritin levels less than 30 ng/mL. We also did not assess
factors like socioeconomic status which could affect our re-
sults. Finally, the present study was not statistically powerful
enough to detect a difference between two groups in the pri-
mary outcome, 25(OH)D (~ 23%).
Conclusions
To sum up, we could not show additional effects of iron plus
vitamin D intake on bone turnover, inflammatory, oxidative
stress, and metabolic markers among healthy females with Hb
≤ 12.7 g/dL and 25OHD ≤ 29 ng/mL vitamin D.
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